Blood markers may forecast pregnancy risks in autoimmune disorder
NCT ID NCT02855047
First seen Nov 21, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This study looked at 513 women with antiphospholipid syndrome (APS) starting a new pregnancy. Researchers measured two blood markers (PGF and sFlt1) before and after the first dose of a standard blood thinner. The goal was to see if changes in these markers could predict serious pregnancy problems like preeclampsia, placental abruption, or poor fetal growth. The study did not test a new treatment but aimed to improve risk prediction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Nîmes - Hôpital Universitaire Carémea
Nîmes, 30029, France
Conditions
Explore the condition pages connected to this study.